Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Glycemic Control With Triple Pathway Approach Through Empagliflozin-Linagliptin-Metformin

NCT06862739 is registered in ClinicalTrials.gov with Nabiqasim Industries (Pvt) Ltd as lead sponsor.

NCT NCT06862739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06862739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Glycemic Control With Triple Pathway Approach Through Empagliflozin-Linagliptin-Metformin
Lead sponsor
Nabiqasim Industries (Pvt) Ltd
Phase
Phase 4
Overall status
Recruiting
Start date
October 30, 2025
Completion date
June 30, 2026
Enrollment
800 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2 dm